Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Julphar
Express Scripts
Healthtrust
Chubb
Harvard Business School
Teva
Medtronic

Generated: September 20, 2018

DrugPatentWatch Database Preview

Teva Pharms Intl Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS INTL, and what generic alternatives to TEVA PHARMS INTL drugs are available?

TEVA PHARMS INTL has two approved drugs.

There are ten US patents protecting TEVA PHARMS INTL drugs.

Summary for Teva Pharms Intl
US Patents:10
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Teva Pharms Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes 7,387,793 ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes 9,399,025 ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes 7,544,372 ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes 9,375,410 ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes 7,820,203 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARMS INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11

Non-Orange Book US Patents for Teva Pharms Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Try a Free Trial
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Try a Free Trial
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Try a Free Trial
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Mallinckrodt
Moodys
Farmers Insurance
US Army
Merck
Colorcon
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.